Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (May 2020)
13 slides from Sona Nanotech's investor presentation, May 2020
Slide 1: Enabling Next Generation Detection Sensitivity for Point-of-Care Biological Diagnostics
Enabling Next Generation Detection Sensitivity for Point-of-Care Biological Diagnostics
Slide 2: Sona Nanotech at a Glance
• Developer of novel technology for lateral flow tests: gold nanoparticles • Proprietary technology uses ‘gold nanorods’ to detect lower concentrations of biomarkers • Enables both improved detection in existing tests (pregnancy, drugs, infection, etc.) and tests not previously possible due to their
Slide 3: SONA Team and Scientific Advisory Team
SONA Team Scientific Advisory Team DARREN ROWLES, CEO DR. CATHERINE J. MURPHY • 14 years experience with nanoparticle diagnostics at BBI Solutions Cathy is the Peter C. and Gretchen Miller Markunas Professor of • Managed BBI Solutions flagship product ranges – gold and lateral flow services Chemistr
Slide 4: A Large and Growing Market Opportunity
Market Segment split – Est % • Value of rapid tests sold globally growing at 7.8%* CAGR • Expired patents of base LF technology allowing for new 5.6% 6.0% Cardio entrants into market Infectious Disease 2.0% Auto Immune • Health care economics driving demand for more effective and fertility 6.0% Food
Slide 5: Lateral Flow Assay Overview
• Lateral flow tests use a nitrocellulose membrane, coloured nanoparticles such as Sona nanorods, and typically antibodies, to produce results. • When a sample (blood, saliva, milk etc) is added, the sample will flow along the test device passing through the conjugate pad into the nitrocellulose mem
Slide 6: Sona powered multiplexed lateral flow assays
Sona powered multiplexed lateral flow assays GOLD NANOROD TECHNOLOGY MULTIPLEXED DEVICES • Microscopic rod shape particles • Detect more than one biomarker for a disease • CTAB free • Increase clinical relevance of the test results • Multiple distinct sizes • Detect multiple diseases in one test • C
Slide 7: Competitive Advantage: Sona's 'Gold Nanorods'
Example of Gold Nanorod Comparison of nanorods vs nanospheres in established Hepatitis B test in market for >5 years. Indicative Performance: Hepatitis Test • Current nanosphere detection limit is 4 UPEI/ml • Gold nanorods (GNRs) enable detection at 2.0 UPEI/ml, a 100% improvement • Sona’s GNR techn
Slide 8: Sona's Gold Nanorod Manufacturing
Sona manufactures proprietary nanomaterials (GNRs) that enable quick, highly sensitive and inexpensive rapid tests • Unique gold nanorod (“GNR”) technology enabling next generation of lateral flow tests § Microscopic rod-shape particles § Enables more sensitive tests than by using nanospheres § Only
Slide 9: The Covid-19 Diagnostic Challenge and Our Partners
No rapid, ‘point-of-care’ test of the virus currently exists • Unable to screen those requiring tests in order to triage individuals and lessen the burden on the medical system. • Currently, all tests must be sent to labs, limiting the number of tests being conducted daily. • Limited machinery, tech
Slide 10: A Rapid, 'Point-of-Care' Covid-19 Antigen Test
A Rapid, ‘Point-of-Care’ Covid-19 Molecular Tests Serological Tests Antigen Tests Antigen Test Test Type: Polymerase Chain Reaction (PCR) Lateral Flow (LFA/LFIA) Lateral Flow (LFA/LFIA) Location: In laboratory Point of care (POC) POC • Started developing qualitative lateral flow assay to detect Time
Slide 11: Revenue Generation
Researchers License and Royalty Rapid Test Sales • Direct sales of gold nanorods • Annual or onetime license fee to • Direct sales of Sona and conjugates to lateral flow use technology in lateral flow test. developed/branded rapid test kits developers and researchers. • Royalty based on in-market sa
Slide 12: Lateral Flow Diagnostic Applications
Drugs of Food and Consumer health Medical Environmental Military Animal abuse beverage pharmaceuticals diagnostics testing diagnostics diagnostics • >1Bn tests produced in 2017* • Veterinary diagnostics includes disease testing in agricultural animals and pets • Medical diagnostics includes tests fo
Slide 13: Contact Information
Darren Rowles David Regan President and CEO Strategic Advisor M: +1-902-880-9925 M: +1-902-448-1416 T: 1-902-442-0653 david@sonanano.com LinkedIn: Darren Rowles 1969 Upper Water Street, Suite 2001, 20th Floor, Purdy’s Tower II Halifax, Nova Scotia, Canada, B3J 3R7 www.sonanano.com 12 Contact Informa